Moderna Inc. announced Tuesday that its vaccine for respiratory syncytial virus (RSV) in adults over 60 years old is 84% effective at preventing lower respiratory tract diseases.
Based on the results, the Cambridge company plans to submit the vaccine for approval by July at the latest.
STAY IN THE KNOW
 |
Watch NBC10 Boston news for free, 24/7, wherever you are. |
 |
Get Boston local news, weather forecasts, lifestyle and entertainment stories to your inbox. Sign up for NBC Boston’s newsletters. |
More on this story from Boston Business Journal
Get top local stories in Boston delivered to you every morning. Sign up for NBC Boston's News Headlines newsletter.
Copyright Boston Business Journal
